• Explore /
  • Poster
  • / KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).

KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

Christopher Hoimes

Christopher J. Hoimes

Duke Cancer Institute, Durham, NC

Christopher J. Hoimes , Julie N Graff , Scott T. Tagawa , Clara Hwang , Deepak Kilari , A. J. Ten Tije , Aurelius Omlin , Raymond S. McDermott , Ulka N. Vaishampayan , Tony Elliott , Winald R. Gerritsen , Haiyan Wu , Jeri Kim , Charles Schloss , Johann S. De Bono , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02787005

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5543)

DOI

10.1200/JCO.2020.38.15_suppl.5543

Abstract #

5543

Poster Bd #

124

Abstract Disclosures

Similar Posters

First Author: Emmanuel S. Antonarakis

First Author: Sumit Kumar Subudhi

First Author: Benedito A. Carneiro

First Author: Rahul Raj Aggarwal